My suggestion is to use the "new"term. We included it in the new revision of ISO 14971 because both the US FDA and MDR uses them, as mentioned by Craiglab. One of the reasons is that it makes it more clear that the benefit is important (when we say risk-benefit it may give the idea that the risk is more important). Also, this was changed to make it more clear that the manufacturers have to go after the benefits (in the past, the generic idea of regulations was that, if you managed the risk, the benefit would be there. Current and newer regulations will require that the benefit is measured, such as the MDR, when balancing it with the risk).